Global Oncology Diagnostics in IVD Research Report 2023: Personalized Medicine Revolutionizes Cancer Treatment, Boosting Diagnostic Tech Advancements – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Oncology Diagnostics in IVD Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering.


The global oncology diagnostics in IVD market is poised for substantial growth, primarily propelled by the rising cancer incidence rates, advancements in diagnostic test technologies, an upsurge in screening procedures, and proactive government initiatives.

The market’s competitive landscape has prompted leading companies to make substantial investments in research and development, aimed at introducing novel diagnostic tests that offer enhanced accuracy and insights.

The burgeoning field of personalized medicine is rapidly gaining momentum, striving to customize cancer treatment approaches according to the unique requirements of individual patients. This progress is greatly facilitated by the evolution of cutting-edge diagnostic technologies designed to identify genetic anomalies responsible for driving cancer progression.

At the core of oncology diagnostics lies genomic profiling, a technique that enables the precise detection of mutations and variations in genes linked to cancer. This enables healthcare practitioners to fine-tune treatment plans based on genetic insights, leading to better treatment outcomes and the ability to predict the prognosis of cancer patients.

As these diagnostic tools continue to evolve, they empower medical professionals to make informed decisions that can significantly impact patient care and management.

Growth Opportunities

Growing Trend of Oncology Screening

Advanced, Integrated Diagnostics Labs

Increased Adoption of Liquid Biopsy Testing

Smart Diagnostics with AI

Unlocking CDx Opportunities in APAC

Unleashing Opportunities in Lung Cancer Diagnostics and Screening

A selection of companies mentioned in this report includes

Abbott Laboratories

Genomic Health

Guardant Health

Illumina

Invitae Corporation

Myriad Genetics

Natera

PerkinElmer

QIAGEN

Roche Diagnostics

Key Topics Covered:

1. Strategic Imperatives

Why is it Increasingly Difficult to Grow?

The Strategic Imperative

The Impact of the Top 3 Strategic Imperatives on the Global Oncology Diagnostics in IVD Industry

Growth Opportunities Fuel the Growth Pipeline Engine

2. Growth Opportunity Analysis

Scope of the Study

Segmentation by Test Type

Segmentation by Cancer Type

Segmentation by Application

3. Oncology Diagnostics in IVD: An Overview

Patient Care Continuum

Role of Oncology Diagnostics in Precision Medicine

The Role of Diagnostics is Crucial in the Evolving Precision Medicine Ecosystem

Trends Driving Cancer Testing

4. Oncology Diagnostics in IVD: Market Dynamics

Growth Metrics

Growth Drivers

Growth Restraints

Key Oncology Diagnostics Opportunities and the Impact on Business Dynamics

5. Oncology Diagnostics in IVD: Market Size and Forecast

Oncology Incidence Rate

Age-standardized Global Incidence Rates Per Sex – Top 10 Cancers

Forecast Assumptions

Revenue Forecast

Revenue Forecast Analysis

Revenue Forecast by Region

Revenue Forecast Analysis by Region

HRSA’s Investment in the Accelerating Cancer Screening Program (the United States)

Revenue Forecast by Test Type

Revenue Forecast Analysis by Test Type

Revenue Forecast by Cancer Type

Revenue Forecast Analysis by Cancer Type

Overview of Oncology Diagnostic Test Reimbursement by Region

Revenue Forecast by Application

Revenue Forecast Analysis by Application

6. Competitive Analysis

Competitive Environment

Key Competitors

Revenue Share by Tier

Companies to Watch – QIAGEN

Companies to Watch – Roche Diagnostics

Companies to Watch – Guardant Health

Companies to Watch – Myriad Genetics

Companies to Watch – Genomic Health

Companies to Watch – PerkinElmer

Companies to Watch – Invitae Corporation

Companies to Watch – Abbott Laboratories

Companies to Watch – Illumina

Companies to Watch – Natera

Global Oncology Diagnostics Market: Notable Activities

Competitive Mapping by Application

Oncology Diagnostic Participants: Competitive Benchmarking

Global Oncology Diagnostics Companies: Strategic Imperatives

7. Companion Diagnostics

CDx Overview

CDx Market Trends

CDx Global Reimbursement Overview

CDx Reimbursement Challenges

CDx FDA Approvals for Oncology Drugs and Biomarkers

CDx Targets by Company

Companion Diagnostic Partnerships

List of FDA-cleared/approved Companion Diagnostic IVD Devices

8. Liquid Biopsy

Liquid Biopsy: A Step Ahead in Biomarker Analysis

Potential of Liquid Biopsies to Improve Screening and Triage Pathways

miRNAs as Potential Cancer Biomarkers

Liquid Biopsy Companies in the Industry

Liquid Biopsy Regulatory Landscape

FDA-approved Liquid Biopsy Tests

Liquid Biopsy Technology and Recent Developments

Advancing Liquid Biopsies: Embracing Multiomics for Comprehensive Insights

Liquid Biopsy Market Opportunities

Liquid Biopsy Commercialization

For more information about this report visit https://www.researchandmarkets.com/r/im9cov

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.